The process cannot access the file 'D:\home\site\wwwroot\QualityLog.txt' because it is being used by another process. TAP Homepage - The ASCO Post
Advertisement

Advertisement

Emil J Freireich, MD, FAACR, Honored With AACR Award for Lifetime Achievement in Cancer Research

The American Association for Cancer Research (AACR) recognized Emil J Freireich, MD, FAACR, with the 2019 AACR Award for Lifetime Achievement in Cancer Research...

OneOncology Announces Lee Schwartzberg, MD, FACP, as Chief Medical Officer

OneOncology, the national partnership of community oncologists, has announced that Lee Schwartzberg, MD, FACP, has been named Chief Medical Officer...

Issues in Oncology

FDA Oncology Center of Excellence Issues Annual Report

The U.S. Food and Drug Administration (FDA) Oncology Center of Excellence (OCE) has issued its 2018 Annual Report, including updates on regulatory reviews and initiatives...


Advertisement
Issues in Oncology

Physician Wellness: Time to Heal the Healer

Physician wellness is emblazoned upfront in the news with attention-seeking headlines on a daily basis. The fact that one or two physicians commit suicide every day...

The Skin Cancer Foundation Awards $125,000 in Research Grants

The Skin Cancer Foundation hosted its member reception on March 1 during the American Academy of Dermatology (AAD) Annual Meeting. As part of the reception...

Advertisement




More Top Stories

Kidney Cancer

Brian I. Rini, MD, on Renal Cell Cancer: Risk Stratification After Resection of Localized Disease

Lung Cancer

Local Consolidative Therapy Linked to Survival Benefit in Oligometastatic Non–Small Cell Lung Cancer

A retrospective analysis of nearly 200 patients treated with local consolidative therapy for oligometastatic non–small cell lung cancer (NSCLC) has found improved overall survival associated with aggressive consolidation.1 According to data presented at the 2019 Multidisciplinary Thoracic Cancers...

Advertisement

OPTIMISMM: Addition of Pomalidomide to Bortezomib/Dexamethasone in Pretreated Relapsed or Refractory Multiple Myeloma

In the phase III OPTIMISMM trial, reported by Richardson et al in The Lancet Oncology, researchers found that the addition of pomalidomide to bortezomib/dexamethasone improved progression-free survival in relapsed or refractory multiple myeloma previously treated with lenalidomide. Study Details...

Lung Cancer
Issues in Oncology

Shraddha M. Dalwadi, MD, MBA, on Non–Small Cell Lung Cancer: What Contributes to Disparities in Treating Stage I Disease

Kidney Cancer
Immunotherapy

First-Line Therapy for Advanced Kidney Cancer: Combination Treatment vs Sunitinib

  TWO RECENTLY reported phase III trials have shown the benefits of combination therapy vs sunitinib in the first-line treatment of advanced renal cell carcinoma. As reported in The New England Journal of Medicine by Brian I. Rini, MD, of Cleveland Clinic Taussig Cancer Institute, and...

Kidney Cancer

TIVO-3: Tivozanib vs Sorafenib in Refractory Advanced Renal Cell Carcinoma

The TIVO-3 trial was conducted to confirm progression-free survival results from the TIVO-1 trial, which found an improvement in median progression-free survival in patients with metastatic renal cell carcinoma treated with tivozanib vs sorafenib. Findings from TIVO-3 were presented by Rini et al...

Early-Stage Study of Nivolumab Alone or in Combination With Cisplatin/Gemcitabine in Biliary Tract Cancer

In a Japanese phase I trial reported by Ueno et al in The Lancet Gastroenterology & Hepatology, researchers found nivolumab showed activity and had a manageable safety profile in patients with unresectable or recurrent biliary tract cancer. Methods The open-label phase I trial was conducted...

Gastroesophageal Cancer
Gastrointestinal Cancer

Manish A. Shah, MD, on Gastric Cancer: Results From the GAMMA-1 Study on First-Line Combination Therapy

ASCO Launches FY 2020 Advocacy Campaign for Federally Funded Cancer Research

ASCO HAS KICKED OFF its Fiscal Year (FY) 2020 advocacy campaign in support of increased funding for federal cancer research. ASCO is urging Congress to provide $41.6 billion to the National Institutes of Health (NIH)—a $2.5 billion increase from FY 2019— and $6.5 billion to the National Cancer...

Advertisement

ACCURE Trial: Improving Racial Disparities in Treatment for Patients With Early-Stage Lung and Breast Cancers

Results from a study published by Cykert et al in The Journal of the National Medical Association show that a pragmatic system-based intervention within cancer treatment centers can nearly eliminate existing disparities in treatment and outcomes for black patients with early-stage...